23 February 2018

# ENHANCING HONG KONG'S LISTING FRAMEWORK

Consultation on Listing Regime for Companies from Emerging and Innovative Sectors



Charles Li David Graham James Fok Grace Hui




1

**Background to the Consultation** 









# **BACKGROUND TO THE CONSULTATION**



# What Did We Set Out to Achieve?

# OUR GOAL:



Enhance Hong Kong's competitiveness as a global financial centre



Attract high growth companies from emerging and innovative sectors



**Diversify Hong Kong's market** 

### **Issues Identified**



No regime for pre-revenue emerging and innovative companies



No regime for non-standard governance features



Restrictions on secondary listings



# Proposed Way Forward Following "New Board" Concept Paper Feedback





# What Has Been Done Since Publication of the "New Board" Consultation Conclusions in December 2017?



### **Engaged with practitioners**

- Feedback on appropriate listing parameters / conditions / safeguards / requirements
- Specialist advice on Biotech Companies



### **Engaged with issuers**


- Better understanding of real issues / market needs
- Ensure listing regime is globally competitive



### **Detailed regulatory discussion**

- SFC → appropriate investor protections
- Listing Committee → detailed Listing Rules requirements and practical operation of the new regime







# **CONSULTATION PROPOSALS**



## **Contents of This Consultation**

### **Proposals**





# CONSULTATION PROPOSALS BIOTECH CHAPTER



# **Principles Underlying Biotech Issuer Suitability**



### **Product regulated by Competent Authority**

- US Food and Drug Administration (FDA), China Food and Drug Administration (CFDA), European Medicines Agency (EMA)
- Other authorities will be considered on a case-by-case basis



### Past concept stage

- Completed Phase I and received no objection to commence Phase II (or later)
- Product subject to human testing



### Meaningful investment from at least one Sophisticated Investor

• To provide a level of validation from an experienced third party investor



# **Proposed Listing Eligibility**

### SUITABILITY FOR LISTING -

**PRODUCT** At least one Core Product<sup>(1)</sup> beyond concept stage

### **RESEARCH AND DEVELOPMENT**

Primarily engaged in R&D of its Core Product(s) for a minimum of 12 months

### IPO

Primary reason for listing is to raise capital for R&D to bring its Core Product(s) to commercialisation

### PATENTS

Durable patent(s), registered patent(s), patent application(s) and/or intellectual property in relation to its Core Product(s)

### SOPHISTICATED INVESTOR<sup>(2)</sup>

Meaningful investment<sup>(3)</sup> for at least 6 months before IPO (which must remain at IPO)

### Specific guidance for Biotech Issuers

### Pharmaceutical (small molecule drugs)

- completed Phase I or, for previously approved products (e.g. FDA's 505(b)(2)) – at least one trial on human subjects; and
- no objection to commence Phase II

#### **Biologics**

- completed Phase I, or for biosimilar at least one trial on human subjects; and
- no objection to commence Phase II (or later)

### Medical Devices (including diagnostics)

- Class II medical device (or equivalent) or above;
- at least one trial on human subjects;
- endorsed or no objection to proceed to further clinical trials or commence sales of the device

### **Other Biotech Products**

- will be considered on a case-by-case basis;
- need to demonstrate it is beyond concept stage;
- appropriate framework or objective indicator for investors to make an informed investment decision


11

- (1) A Biotech Product(s) that is required by applicable laws, rules or regulations to be evaluated and approved by a Competent Authority based on data derived from clinical trials (i.e. on human subjects) before it could be marketed and sold in the market regulated by that Competent Authority which forms the basis of a Biotech Company's listing application under Chapter 18A of the Listing Rules
- (2) By reference to factors such as net assets or assets under management, relevant investment experience, and the investor's knowledge and expertise in the relevant field

(3) Being more than just a token investment

# **Additional Listing Requirements and Shareholder Protections**

Сар	■ ≥HK\$1.5billion
Track Record	<ul> <li>In its current line of business for at least 2 financial years</li> <li>Substantially the same management</li> </ul>
Working Capital	<ul> <li>125% of the group's costs for at least next 12 months (after taking into account the proceeds of the IPO)</li> <li>Must substantially consist of (a) general, administrative and operating costs; and (b) R&amp;D costs</li> </ul>
Restriction on Cornerstones	<ul> <li>Cornerstones will not count towards minimum initial public float requirement at listing or during 6 months lock-up</li> <li>Existing pre-IPO investors can participate in IPO and only IPO shares subscribed for will not count towards minimum initial public float requirement</li> </ul>
Special Measures to Manage Risks	<ul> <li>Fundamental change of principal business will require consent from the Exchange</li> <li>Accelerated de-listing process (12 months to re-comply with requirement)</li> <li>Stock marker "B" at the end of its stock name</li> </ul>



# CONSULTATION PROPOSALS WVR CHAPTER



# **Proposed Listing Eligibility**



### **NEW APPLICANTS ONLY**

### HIGH MARKET CAP.

■ ≥HK\$10bn with ≥HK\$1bn in revenue if <HK\$40bn

### INNOVATIVE

as defined by guidance

### SUCCESSFUL

track record of high business growth

### **EXTERNAL VALIDATION**

meaningful third party investment

WVR BENEFICIARIES

### **INDIVIDUALS ONLY**

- materially responsible for growth of the business
- separate consultation on corporate beneficiaries

### **DIRECTORS ONLY**

at listing and afterwards

### SHAREHOLDING

≥10% and ≤50% at listing (collectively)

### **TRANSFERS PROHIBITED**

- natural sunset
- allow trusts and legitimate tax planning

## **Additional Listing Requirements and Shareholder Protections**

- No increase in proportion of WVRs after listing
- Share-based WVR only with maximum 10x voting power vs. ordinary shares
- Non-WVR shareholders must have 10% of voting power
- Fundamental matters voted on a "one-share, one-vote" basis
  - changes to constitutional documents;
  - INED appointment & removal;
  - auditor appointment & removal;
  - variation of rights attached to any class of shares; and
  - voluntary winding-up of the listed issuer

### Enhanced disclosure

- Warnings on listing documents and communications
- "W" stock marker

### Enhanced corporate governance


- Corporate governance committee to review, monitor and report on compliance with WVR safeguards
- Ongoing compliance adviser to provide advice to issuers on compliance with WVR safeguards and rules

### Constitutional backing and legal remedies

- WVR safeguards must be incorporated into constitutional documents
- WVR beneficiaries must give undertaking to the issuer to comply with WVR safeguards



SAFEGUARDS



# CONSULTATION PROPOSALS SECONDARY LISTING CHAPTER



# **Qualifying Criteria for New Secondary Listing Regime**





# **Secondary Listing of Qualifying Issuers**

GRANDFATHERED

**GREATER CHINA COMPANIES** 

**NON-GRANDFATHERED** GREATER CHINA COMPANIES NON-GREATER CHINA COMPANIES

### **GRANDFATHERED GREATER CHINA COMPANIES:**

- Greater China companies that primary listed on a Qualifying Exchange on or before 15 Dec 2017
- Must demonstrate how they are subject to Key Shareholder Protections<sup>(1)</sup> (changes to constitutional documents may be required, as necessary)
- No need to comply with ongoing primary Listing Rule requirements (e.g. notifiable transaction and connected transaction rules)
- Can secondary list with their existing WVR structures and VIE structures intact (if they have them)
- No need for them to comply with WVR safeguards (other than those requiring disclosure)
- If "bulk of trading" moves permanently to Hong Kong then primary Listing Rule requirements would apply but not WVR safeguards (other than disclosure requirements)



#### (1) For example:

- issuer must hold an annual general meeting at least every 15 months, give reasonable notice of meetings and members to have the right to speak and vote at the shareholders' meeting
- super-majority vote of members is required to approve fundamental matters (material changes to constitutional documents, variation of rights attached to any class of shares and voluntary winding-up)
- · appointment, removal and the remuneration of auditors require the approval of a majority of shareholders or other body independent of the board of directors

# **Secondary Listing of Qualifying Issuers**

**GRANDFATHERED** GREATER CHINA COMPANIES **NON-GRANDFATHERED** GREATER CHINA COMPANIES

NON-GREATER CHINA COMPANIES

### **NON-GRANDFATHERED GREATER CHINA COMPANIES:**

- Greater China companies that primary listed on a Qualifying Exchange <u>after 15 Dec 2017</u>
- Must vary constitutional documents as required by existing Rules to meet "equivalence" requirements
- No need to comply with ongoing primary Listing Rule requirements (e.g. notifiable transaction and connected transaction rules)
- WVR structures and VIE structures (if they have them) must conform to all primary Listing Rule requirements
- If "bulk of trading" moves permanently to Hong Kong then primary Listing Rule requirements would apply
- Approach designed to deter "regulatory arbitrage"



# **Secondary Listing of Qualifying Issuers**

**GRANDFATHERED** GREATER CHINA COMPANIES **NON-GRANDFATHERED** GREATER CHINA COMPANIES NON-GREATER CHINA COMPANIES


### NON-GREATER CHINA COMPANIES:

- Any company from outside of Greater China primary listed on a Qualifying Exchange
- Must demonstrate how they are subject to Key Shareholder Protections<sup>(1)</sup> (changes to constitutional documents may be required, as necessary)
- No need to comply with ongoing primary Listing Rule requirements (e.g. notifiable transaction and connected transaction rules)
- Can secondary list with their existing WVR structures and VIE structures intact (if they have them)
- No need for them to comply with WVR safeguards (other than those requiring disclosure)
- No change if "bulk of trading" moves permanently to Hong Kong



#### (1) For example:

- issuer must hold an annual general meeting at least every 15 months, give reasonable notice of meetings and members to have the right to speak and vote at the shareholders' meeting
- super-majority vote of members is required to approve fundamental matters (material changes to constitutional documents, variation of rights attached to any class of shares and voluntary winding-up)
- appointment, removal and the remuneration of auditors require the approval of a majority of shareholders or other body independent of the board of directors



### TIMETABLE AND NEXT STEPS







HKEX invites market views on the proposals and the Listing Rules to implement them





